April 26, 2024
At its April 2024 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) made recommendations for Fruzaqla, Truqap, and Eribulin Baxter […]
April 26, 2024
TOPLINE: In patients with non–small cell lung cancer (NSCLC) who have metastases to the brain only, definitive treatment to the primary site improved overall survival outcomes […]
April 25, 2024
Overall, cancer mortality in the United States has declined over the past few decades. But there are some exceptions. Deaths from endometrial cancer, for instance, have […]
April 25, 2024
For patients with relapsed/refractory follicular lymphoma (R/R FL), chimeric antigen responder (CAR) T-cell therapy offers the best chance of survival, despite its high rate of serious […]
April 24, 2024
In October, the US Food and Drug Administration (FDA) pressed pause on a trial studying a new lymphoma drug after a patient died. A few months […]
April 23, 2024
The first-in-class complement factor D inhibitor danicopan (Voydeya) has been approved by the European Commission as an add-on agent for certain patients with the rare disease […]
April 23, 2024
The US Food and Drug Administration (FDA) has approved the first-in-class interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln (Anktiva), plus bacillus Calmette-Guérin (BCG), for the treatment of […]
April 23, 2024
When should patients with advanced or metastatic non–small cell lung cancer receive osimertinib plus platinum-based chemotherapy in the frontline setting and when is osimertinib enough on […]
April 23, 2024
TOPLINE: A recent survey-based study found that only 4% of cancer survivors reported adhering to all four American Cancer Society (ACS) nutrition and physical activity guidelines, […]